<DOC>
	<DOCNO>NCT01369628</DOCNO>
	<brief_summary>The sponsor electively terminate study risk mitigation measure , deem necessary unforeseen safety event , could effectively implement within protocol maintain study timeline within reasonable time frame .</brief_summary>
	<brief_title>Atacicept Lupus Nephritis Patients Taking Stable Regimen Mycophenolate Mofetil</brief_title>
	<detailed_description>This study evaluate atacicept 's effect subject lupus nephritis , least 2 g/day protein urine , already take mycophenolate mofetil . The evaluation include concentration atacicept blood , effect atacicept immunoglobulin ( antibody ) , side effect . The first subject give low dose . Following periodic review trial data , subsequent subject plan receive one 2 progressively high dos atacicept .</detailed_description>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Male female subject , ≥ 18 year age , provide write informed consent Subjects must diagnosis SLE satisfy ≥ 4 11 ACR criterion , must renal biopsy screen within previous 18 month demonstrate class III ( A A/C ) , IV ( A A/C ) , V , concomitant III/V IV/V LN define International Society Nephrology/Renal Pathology Society ( ISN/RPS ) . Subjects must urine protein : creatinine ratio ≥ 2 mg/mg ( ≥ 226.2 mg/mmol ) , either positive test antinuclear antibody ( ANA ) ( HEp2 ANA ≥ 1:80 ) and/or antidouble strand deoxyribonucleic acid ( dsDNA ) ( ≥ 30 IU/mL ) screening . Subjects must start induction therapy LN least 5 month prior Trial Day 1 , consider receive continuous treatment LN 5 month prior Trial Day 1 , receive stable dose MMF ≥ 1 g/day , without corticosteroid , least 8 week prior Trial Day 1 . Recent change immunosuppressant , ACD inhibitor ARBs Use azathioprine , cyclosporine , tacrolimus , cyclophosphamide biologics within 8 week prior Trial Day 1 . Serum IgG &lt; 6 g/L Estimated Glomerular Filtration Rate ( GFR ) ≤ 30 mL/min per 1.73 m2 History Demyelinating Disease Significant Hematuria and/or Proteinuria due reason ( ) LN . Evaluation do accord local standard care Breast feed pregnancy Legal Incapacity limit legal capacity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Open label</keyword>
	<keyword>Dose Escalating</keyword>
	<keyword>Phase Ib</keyword>
</DOC>